In the latest trading session, Aphria Inc. closed at $9.57, marking a -1.95% move from the previous day. This move lagged the S&P 500's daily gain of 0.3%. Elsewhere, the Dow lost 0.38%, while the tech-heavy Nasdaq added 0.44%.
Prior to today's trading, shares of the company had gained 16.47% over the past month. This has outpaced the Medical sector's gain of 2.07% and the S&P 500's gain of 2.91% in that time.
APHA will be looking to display strength as it nears its next earnings release. On that day, APHA is projected to report earnings of -$0.04 per share, which would represent a year-over-year decline of 166.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.11 million, up 403.74% from the year-ago period.
APHA's full-year Zacks Consensus Estimates are calling for earnings of $0.11 per share and revenue of $129.24 million. These results would represent year-over-year changes of -21.43% and +344.96%, respectively.
Any recent changes to analyst estimates for APHA should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 20.54% higher within the past month. APHA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, APHA is currently trading at a Forward P/E ratio of 86.76. Its industry sports an average Forward P/E of 25.01, so we one might conclude that APHA is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Aphria Inc. (APHA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Aphria Inc. closed at $9.57, marking a -1.95% move from the previous day. This move lagged the S&P 500's daily gain of 0.3%. Elsewhere, the Dow lost 0.38%, while the tech-heavy Nasdaq added 0.44%.
Prior to today's trading, shares of the company had gained 16.47% over the past month. This has outpaced the Medical sector's gain of 2.07% and the S&P 500's gain of 2.91% in that time.
APHA will be looking to display strength as it nears its next earnings release. On that day, APHA is projected to report earnings of -$0.04 per share, which would represent a year-over-year decline of 166.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.11 million, up 403.74% from the year-ago period.
APHA's full-year Zacks Consensus Estimates are calling for earnings of $0.11 per share and revenue of $129.24 million. These results would represent year-over-year changes of -21.43% and +344.96%, respectively.
Any recent changes to analyst estimates for APHA should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 20.54% higher within the past month. APHA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, APHA is currently trading at a Forward P/E ratio of 86.76. Its industry sports an average Forward P/E of 25.01, so we one might conclude that APHA is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.